Moleculin Biotech, Inc. (NASDAQ:MBRX) announced dosing of subjects in its Phase 1a clinical study of WP1122 in healthy volunteers for the treatment of COVID-19.
The first-in-human Phase 1a study will evaluate the safety and pharmacokinetics (PK) of WP1122, Moleculin's lead metabolism/glycosylation inhibitor.
